Author Archives: Steve Walker

European drug regulator comes out of hibernation in new Dutch headquarters, rivaling the FDA with rulings; well, just for one week.

It may have taken nearly 6 months and perhaps a Fourth of July holiday-shortened work week here in the US, but the European Medicines Agency (EMA) finally issued some new… Read more »

BioNTech raises $325M in Series B round, skipping IPO for now

The News: Germany’s BioNTech raises eye-popping €290M ($325M) in Series B round to fund personalized mRNA cancer vaccines, eschewing IPO for now. Just where does German biotech stand vis-à-vis the… Read more »

Healthcare IPOs lead 2Q19 to 5-year record.

During the second quarter ending June 30, 62 IPOs raised $25.0 billion, the most active quarter by deal count in four years and the most capital raised in five years…. Read more »

Brexit referendum slowing the European Medicines Agency’s operations to a crawl.

The News: The European Medicines Agency (EMA) recently addressed its concerns for ensuring business continuity and staff retention which had become huge challenges caused by the Brexit referendum. The EMA… Read more »

Investors shell out $619M in huge health-sector IPO stampede.

The News: Four biotechs and a genome-sequencing player firm grabbed their brass rings last week, cashing in with $619 million in total IPO funding. That means that with one week… Read more »

Medical Stock Spotlight: Three winners from last week hit with profit-taking, while one big loser rebounds. This week, Provention shines, but Cymabay bombs.

Stocks continue to be whipsawed by sudden upward, then plunging, prices, only to reverse direction again as political and economic uncertainty reigns supreme. Here are four prime examples of this… Read more »

The worldwide battle over health spending, especially high drug prices, and whether it’s actually worth it. The view from afar.

Commentary: Steve Walker The “Medicare for All” plan embraced by leading 2020 Democrats looks more lavish than what other advanced countries offer, compounding the cost but also potentially broadening its… Read more »

Healthcare stocks rattled by Trump’s threat to force public pricing disclosure across the entire sector. The top winners, losers, and reasons why.

President Trump is expected to sign an executive order this week that would require for the first time disclosure of prices across the healthcare industry, in a move that officials… Read more »